Solid‐Phase Parallel Synthesis of Photocleavable Bifunctional Molecules Enables Efficient Phenotypic Protein Degrader Discovery
Abstract
Abstract Phenotypic screening offers an effective path for discovering protein degraders, particularly targeting proteins that are poorly characterized or lack sufficient ligand‐binding information. Nonetheless, phenotypic protein degrader discovery (PPDD) faces practical hurdles, such as synthetic complexity in generating chemically diverse libraries and difficulties in reliably identifying degradation‐driven phenotypes in direct‐to‐biology (D2B) assays. In response to these challenges, we developed an integrated PPDD platform that combines optimized solid‐phase parallel synthesis with a robust D2B screening workflow. Leveraging photocleavable linkers and versatile synthetic strategies, this platform facilitates rapid generation of chemically diverse, ready‐to‐screen bifunctional molecule libraries requiring minimal purification. As a proof of concept, we synthesized and phenotypically screened 130 cereblon‐recruiting molecules, leading to several promising protein degradation‐dependent hits. Subsequent hit optimization and target identification validated compound 12–60 as a structurally novel GSPT1 degrader with compelling cellular activity. Overall, our integrated platform represents an efficient and practical toolkit for PPDD, establishing a versatile foundation to accelerate future campaigns and expand the degradable proteome.
Article Details
Authors (11)
Baoli Ding
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti‐Cancer Drug Research College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P.R. China
Jiawen Hu
Rongtian Zhang
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti‐Cancer Drug Research College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P.R. China
Binyan Shou
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti‐Cancer Drug Research College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P.R. China
Mengdie Chen
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti‐Cancer Drug Research College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P.R. China
Li Jiang
Department of Radiation Oncology The First Affiliated Hospital of Guangxi Medical University Nanning China
Meng Yuan
Bo Yang
Qiaojun He
Ji Cao
Cheng‐Liang Zhu
Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti‐Cancer Drug Research College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P.R. China